Loading stock data…
$17.18+0.52 (+3.12%)
NeoGenomics, Inc.
NeoGenomics, Inc. in the Healthcare sector is trading at $17.18 with a market capitalization of $2.0B. Wall Street consensus targets $21.85 (10 analysts), implying a +27.2% move over the next 12 months. The stock is currently 15% below its 52-week high of $20.15, remaining 37.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $201.66M↑ | $186.67M↓ | $190.17M↑ | $187.80M↑ | $181.33M |
| Gross Profit | $91.88M↑ | $80.86M↓ | $83.34M↑ | $80.45M↑ | $77.26M |
| Operating Income | -$9.77M↑ | -$18.24M↓ | -$12.79M↑ | -$19.93M↑ | -$27.59M |
| Net Income | $2.24M↑ | -$17.11M↓ | -$9.88M↑ | -$27.13M↑ | -$45.09M |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical compani...